As of November 7, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Arrowhead Pharmaceuticals Inc. The largest reported stake is BlackRock, Inc.'s, at 10.1%. 14 filings are on record since July 29, 2025 (Schedule 13G/A, July 27, 2026).
Sell to companies like Arrowhead Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 9,301,559 · Shared voting: 0 · Sole dispositive: 9,307,350 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Avoro Capital Advisors LLC · Sole voting: 13,823,383 · Shared voting: 0 · Sole dispositive: 13,823,383 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Vanguard Portfolio Management · Sole voting: 33,548 · Shared voting: 0 · Sole dispositive: 6,384,903 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-31
- · Reporting person: BlackRock, Inc. · Sole voting: 13,849,022 · Shared voting: 0 · Sole dispositive: 14,232,545 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-27
- · Holder: Fmr LLC · Percent: 5.2% · SCHEDULE 13G
Arrowhead Pharmaceuticals Inc has 14 Schedule 13D or 13G filings on record since 2025-07-29. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 10.1% | 14,232,545 | SCHEDULE 13G/A, 2026-07-27 | 2026-06-30 |
| Avoro Capital Advisors LLC | 9.64% | 13,823,383 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Fmr LLC | 6.6% | 9,307,350 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| Vanguard Capital Management | 5.05% | 7,081,293 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| State Street Corporation | 4.6% | 6,371,056 | SCHEDULE 13G, 2025-08-11 | 2025-06-30 |
| Vanguard Portfolio Management | 4.53% | 6,384,903 | SCHEDULE 13G/A, 2026-07-31 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
| Sarepta Therapeutics, Inc. | 0% | 0 | SCHEDULE 13D/A, 2025-08-15 | 2025-08-13 |
Holding shares or following this stake? See who's behind Arrowhead Pharmaceuticals Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Arrowhead Pharmaceuticals Inc and the records around it.
Arrowhead Pharmaceuticals Inc elsewhere on the record
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Scribe Therapeutics, Inc. (Jul 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Arrowhead Pharmaceuticals Inc
Get an email when Arrowhead Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arrowhead Pharmaceuticals Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Arrowhead Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arrowhead Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,849,022 | 0 | 14,232,545 | 0 | SCHEDULE 13G/A, 2026-07-27 |
| Avoro Capital Advisors LLC | 13,823,383 | 0 | 13,823,383 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Behzad Aghazadeh | 13,823,383 | 0 | 13,823,383 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Fmr LLC | 9,301,559 | 0 | 9,307,350 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 9,307,350 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Vanguard Portfolio Management | 33,548 | 0 | 6,384,903 | 0 | SCHEDULE 13G/A, 2026-07-31 |
The latest filing identifies Arrowhead Pharmaceuticals Inc by CUSIP 04280A100 and gives its principal executive office as 177 E COLORADO BLVD, SUITE 700, PASADENA, CA 91105 (SCHEDULE 13G/A, 2026-11-05).
Purpose of Transaction (Item 4)
Sarepta Therapeutics, Inc.
Item 4 of the Original Schedule 13D is hereby amended by adding the following: On August 13, 2025, Sarepta Investments sold 9,265,312 shares of the Issuer's Common Stock at a price of $18.79 per share in a privately negotiated block trade pursuant to Rule 144 of the Securities Act of 1933, as amended (the "Secondary Sale"). Also on August 13, 2025, concurrently with the Secondary Sale, Sarepta, Sarepta Investments and the Issuer entered into a Letter Agreement (the "Letter Agreement") pursuant to which the Issuer agreed to redeem and acquire from Sarepta Investments 2,660,989 shares of the Issuer's Common Stock (the "Redemption") in satisfaction of the obligation of Sarepta to pay the Issuer $49,999,983.31 of the DM1 First Development Milestone Payment (as such term is defined in Section 8.3.1(a)(i) of the Collaboration Agreement). The foregoing description of the Letter Agreement is not complete and is subject to and qualified in its entirety by reference to the full text of such agreement, which is attached as Exhibit 99.5 hereto and incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2025-08-15
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 11.24% | SCHEDULE 13G/A |
| 2025-08-11 | State Street Corporation | 4.6% | SCHEDULE 13G |
| 2025-08-14 | Avoro Capital Advisors LLC | 8.3% | SCHEDULE 13G/A |
| 2025-08-15 | Sarepta Therapeutics, Inc. | 0% | SCHEDULE 13D/A |
| 2026-01-21 | BlackRock, Inc. | 15% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-24 | BlackRock, Inc. | 12.2% | SCHEDULE 13G/A |
| 2026-04-28 | Vanguard Portfolio Management | 5.19% | SCHEDULE 13G |
| 2026-04-29 | Vanguard Capital Management | 5.05% | SCHEDULE 13G |
| 2026-05-06 | Fmr LLC | 5.2% | SCHEDULE 13G |
| 2026-07-27 | BlackRock, Inc. | 10.1% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Portfolio Management | 4.53% | SCHEDULE 13G/A |
| 2026-08-14 | Avoro Capital Advisors LLC | 9.64% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 6.6% | SCHEDULE 13G/A |
Questions about who owns Arrowhead Pharmaceuticals Inc
Who owns Arrowhead Pharmaceuticals Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Arrowhead Pharmaceuticals Inc: BlackRock, Inc. (10.1%, Schedule 13G/A, filed 2026-07-27), Avoro Capital Advisors LLC (9.64%, Schedule 13G/A, filed 2026-08-14), Fmr LLC (6.6%, Schedule 13G/A, filed 2026-11-05) and Vanguard Capital Management (5.05%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of Arrowhead Pharmaceuticals Inc?
By the share each holder's latest filing reports, the largest holders of Arrowhead Pharmaceuticals Inc on this page are BlackRock, Inc. (10.1%), Avoro Capital Advisors LLC (9.64%) and Fmr LLC (6.6%).
When did BlackRock, Inc. buy into Arrowhead Pharmaceuticals Inc?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2026-01-21, reporting 15%; its latest, Schedule 13G/A filed 2026-07-27, reports 10.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Arrowhead Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 16, 2026 | Leadership change: Matt Cohen appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Arrowhead Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.